Pfizer Inflectra — Revenues: increased by 5.2% to $182.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.0%, from $153.00M to $182.00M.
pfe_segment_inflectra_revenues| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $136.00M | $172.00M | $135.00M | $137.00M | $131.00M | $178.00M | $74.00M | $121.00M | $158.00M | $97.00M | $126.00M | $153.00M | $139.00M | $173.00M | $182.00M |
| QoQ Change | — | +26.5% | -21.5% | +1.5% | -4.4% | +35.9% | -58.4% | +63.5% | +30.6% | -38.6% | +29.9% | +21.4% | -9.2% | +24.5% | +5.2% |
| YoY Change | — | — | — | +0.7% | -23.8% | +31.9% | -46.0% | -7.6% | -11.2% | +31.1% | +4.1% | -3.2% | +43.3% | +37.3% | +19.0% |